CCR5 blockade decreases peripheral T‐cell activation, gut GVHD biomarkers (e.g., serum reg3a, CD146), and acute GVHD incidence in allogeneic HCT recipients. The gene discussed is CCR5; the disease is acute graft versus host disease.